Dr Russell Howard is CEO and founder of Oakbio, a Cleantech company in California using microbes to make chemicals from waste carbon dioxide. He was founder and CEO of Maxygen, a US NASDAQ-listed company focused on human therapeutics with several programs in protein pharmaceuticals. Dr Howard also served as the president and scientific director of Affymax Research Institute, employing combinatorial chemistry and high throughput target screening to discover drug leads.
Product Development Review Committee
Dr Russell Howard
Dr George Morstyn
Dr George Morstyn is the former Senior Vice-President and Head of Development at Amgen Inc. He was a member of the executive committee and responsible for global preclinical and clinical development as well as regulatory affairs. Dr Morstyn trained in medical oncology at the National Cancer Institute in the US and was Head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne.
Dr Errol Malta
Dr Errol Malta was appointed a non-executive director of Circadian on 20 August 2009. He is also chairman of the Company’s Product Development Review Committee and a member of the Remuneration Committee. Dr Malta has more than 20 years‘ experience in drug-development within the pharmaceutical industry, including more than 10 years with Amgen Inc, the world’s largest independent biotechnology company. In his role as Product Development Team Leader, Dr Malta was responsible for five successful new-molecule IND submissions to FDA and other regulatory agencies, subsequent Phase I/II programs, and numerous Phase III and IV trials. He has been a consultant to over 20 biotechnology companies in early phase product development in Australia and the United States. Dr Malta has held previous director positions in the Australian biotechnology sector with Alchemia Ltd, Avexa Ltd, NeuProtect Pty Ltd, NexPep Pty Ltd, Promics Ltd and Cortical Pty Ltd. He is a PhD graduate of the University of Melbourne and a Fellow of the Australian Institute of Company Directors.
Mr Carlo Montagner
Carlo Montagner has a wealth of experience in heading global oncology businesses for chemotherapeutic products and has more than 16 years’ experience in the pharmaceutical industry in the US, Europe, Japan and Australia. During his career, Mr Montagner has built specialty oncology practices, managing the strategic integration of both clinical and commercial aspects of drug portfolios. He was Executive Vice President & Global Head of Schering AG/Berlex Labs United States Oncology Business Unit. He has also held various positions at Aventis Pharma, including Head of Oncology & Cardiovascular Business Unit at Sanofi-Aventis Japan and Global Senior Director of Marketing and Medical Affairs, managing the Taxanes chemotherapy portfolio. Mr Montagner is CEO of privately held Specialised Therapeutics Australia Pty Ltd and is a member of the Australian Institute of Company Directors.
Mr Ralph Smalling
Mr Ralph Smalling held positions with Amgen Inc. for over 23 years including vice president of Regulatory Affairs and International Clinical Safety where he oversaw the development of more than 40 antibody and recombinant protein therapy projects through various stages (preclinical to marketing), including US and international responsibilities. Mr Smalling was a member of the industry team that negotiated PDUFA II, and he drafted a number of the provisions included in the FDAMA legislation passed by Congress in 1997. Since 2005 Mr. Smalling has been an independent consultant in Regulatory Affairs and Development, working on protein based products, as well as gene and stem cell therapies. He has also served as interim Director of Quality for a Biotechnology company.
Dr Richard Morgan
Dr Richard Morgan has more than 25 years experience in pharmaceutical research and development including Head of Toxicology at GlaxoWellcome (now GlaxoSmithKline).